Lanlan Zhou

3.0k total citations · 1 hit paper
101 papers, 1.9k citations indexed

About

Lanlan Zhou is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lanlan Zhou has authored 101 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 48 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lanlan Zhou's work include Cell death mechanisms and regulation (14 papers), Cancer-related Molecular Pathways (13 papers) and Cancer therapeutics and mechanisms (12 papers). Lanlan Zhou is often cited by papers focused on Cell death mechanisms and regulation (14 papers), Cancer-related Molecular Pathways (13 papers) and Cancer therapeutics and mechanisms (12 papers). Lanlan Zhou collaborates with scholars based in United States, China and India. Lanlan Zhou's co-authors include Wafik S. El‐Deiry, Cristina I. Truica, Joseph J. Drabick, Subra Suresh, Po‐Hsun Huang, Yuchao Chen, Zhangli Peng, Zhangming Mao, Tony Jun Huang and Ming Dao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Lanlan Zhou

91 papers receiving 1.9k citations

Hit Papers

Acoustic separation of circulating tumor cells 2015 2026 2018 2022 2015 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Acoustic separation of circulating tumor cells
    2015 635 citations Lanlan Zhou, Wafik S. El‐Deiry et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lanlan Zhou United States 22 749 673 543 331 195 101 1.9k
Erik N. K. Cressman United States 20 678 0.9× 705 1.0× 235 0.4× 386 1.2× 113 0.6× 75 2.0k
Zhuo G. Chen United States 25 1.2k 1.6× 524 0.8× 685 1.3× 270 0.8× 355 1.8× 52 2.3k
Jun Mi China 27 1.2k 1.6× 315 0.5× 499 0.9× 809 2.4× 207 1.1× 54 2.2k
Carsten H. Nielsen Denmark 23 657 0.9× 592 0.9× 391 0.7× 173 0.5× 197 1.0× 53 1.9k
Marc Salzberg Switzerland 17 772 1.0× 330 0.5× 584 1.1× 213 0.6× 218 1.1× 39 2.1k
B. Smith United States 24 897 1.2× 447 0.7× 587 1.1× 304 0.9× 170 0.9× 84 2.2k
Sylvie Roberge United States 18 1.1k 1.5× 654 1.0× 578 1.1× 488 1.5× 258 1.3× 39 2.5k
Axel Sckell Germany 20 725 1.0× 328 0.5× 247 0.5× 352 1.1× 130 0.7× 36 1.9k
Xueqing Zou China 21 1.1k 1.4× 323 0.5× 325 0.6× 634 1.9× 102 0.5× 45 1.9k
Dennis Jones United States 22 723 1.0× 433 0.6× 1.0k 1.9× 304 0.9× 479 2.5× 39 2.3k

Countries citing papers authored by Lanlan Zhou

Since Specialization
Citations

This map shows the geographic impact of Lanlan Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lanlan Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lanlan Zhou more than expected).

Fields of papers citing papers by Lanlan Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lanlan Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lanlan Zhou. The network helps show where Lanlan Zhou may publish in the future.

Co-authorship network of co-authors of Lanlan Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Lanlan Zhou. A scholar is included among the top collaborators of Lanlan Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lanlan Zhou. Lanlan Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Powpaka, Samart, et al.. (2025). User presence in online product reviews: The dual effects on purchase intention. Journal of Business Research. 199. 115563–115563.
2.
3.
Wong, Eric T., Robert W. Sobol, Lanlan Zhou, et al.. (2024). Abstract 7591: Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib. Cancer Research. 84(6_Supplement). 7591–7591.
4.
Liu, Jiangang, et al.. (2024). Research on the influence of Spillover effect on dual-channel supply chain under the background of live-streaming marketing. RAIRO. Operations research. 58(6). 4769–4790. 1 indexed citations
5.
Huntington, Kelsey E., Anna D. Louie, Christoph Schorl, et al.. (2023). GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. International Journal of Molecular Sciences. 24(13). 10870–10870. 11 indexed citations
6.
Ni, Ming, Lanlan Zhou, You Lü, et al.. (2023). 63P Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer. Annals of Oncology. 34. S1490–S1490.
7.
Zhou, Lanlan, et al.. (2022). Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia. Frontiers in Oncology. 12. 912689–912689. 1 indexed citations
8.
Ferrarini, Isacco, Anna D. Louie, Lanlan Zhou, & Wafik S. El‐Deiry. (2021). ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics. 20(9). 1572–1583. 28 indexed citations
9.
Zhao, Shuai, Lanlan Zhou, David T. Dicker, et al.. (2021). Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90. Scientific Reports. 11(1). 20871–20871. 13 indexed citations
10.
11.
Tian, Xiaobing, Shengliang Zhang, Lanlan Zhou, et al.. (2021). Targeting the Integrated Stress Response in Cancer Therapy. Frontiers in Pharmacology. 12. 747837–747837. 101 indexed citations
12.
Raufi, Alexander G., Lindsey Carlsen, Shengliang Zhang, et al.. (2021). Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. Frontiers in Pharmacology. 12. 751568–751568. 9 indexed citations
13.
Şahin, İlyas, Shengliang Zhang, Arunasalam Navaraj, et al.. (2020). AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discovery. 6(1). 57–57. 56 indexed citations
14.
Jonasch, Eric, Gregory N. Fuller, Ian E. McCutcheon, et al.. (2017). The role of hepatocyte nuclear factor 1 homeobox B (HNF1B) loss in chromophobe RCC (ChRCC) development. Annals of Oncology. 28. v602–v602. 2 indexed citations
15.
Tan, Carlyn, Lanlan Zhou, & Wafik S. El‐Deiry. (2016). Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Current Colorectal Cancer Reports. 12(3). 151–161. 53 indexed citations
16.
Zhang, Shengliang, Lanlan Zhou, Bo Hong, et al.. (2015). Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Research. 75(18). 3842–3852. 92 indexed citations
17.
18.
Cheng, Hairong, Bo Hong, Lanlan Zhou, et al.. (2012). Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors. Cell Cycle. 11(17). 3312–3323. 28 indexed citations
19.
Thorek, Daniel L.J., et al.. (2010). In Vivo, Multimodal Imaging of B Cell Distribution and Response to Antibody Immunotherapy in Mice. PLoS ONE. 5(5). e10655–e10655. 14 indexed citations
20.
Jiang, Yiguo, et al.. (2009). MicroRNA Expression Profiles and MiR-10a Target in Anti-benzo[a] pyrene-7, 8-diol-9, 10-epoxide-transformed Human 16HBE Cells. Biomedical and Environmental Sciences. 22(1). 14–21. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erik N. K. Cressman Breakdown of academic impact, for papers by Zhuo G. Chen Breakdown of academic impact, for papers by Jun Mi Breakdown of academic impact, for papers by Carsten H. Nielsen Breakdown of academic impact, for papers by Marc Salzberg Breakdown of academic impact, for papers by B. Smith Breakdown of academic impact, for papers by Sylvie Roberge Breakdown of academic impact, for papers by Axel Sckell Breakdown of academic impact, for papers by Xueqing Zou Breakdown of academic impact, for papers by Dennis Jones
Rankless by CCL
2026